Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectafer (ferric carboxymaltose) for treatment of restless legs syndrome
2015-001521-16Phase 3Completed
- Sponsor
- Luitpold Pharmaceuticals
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in restless legs syndrome (RLS) comparing Injectafer (ferric carboxymaltose) with Placebo (2 arms). Primary endpoints: IRLS total score change from baseline to Day 42 and Proportion of patients rated much or very much improved on CGI-I at Day 42. Started Apr 2015; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2015-001521-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001521-16.